Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Neutral 71.4%

Neg 0% Neu 71.4% Pos 0%

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.